Methods: Four agents have been investigated for activity in vitro and in vivo against SHIV 89X6PD : two anionic polymers, dextrin-2-sulphate (D2S) and PRO 2000 (P2K), and two virucidal agents; a non-ionic detergent, nonoxynol-9 (N9) and a cyclic peptide ionophore, gramicidin-D (GD). All four agents were investigated in rhesus macaques, using an intra-vaginal challenge of two inoculations of 1 3 10 4 50% tissue culture infectious doses (TCID) 50 of SHIV 89X6PD .
Results: D2S, P2K, GD and N9 all inhibited SHIV 89X6PD in vitro. In vivo, three out of four control macaques were infected as judged by viral culture, seroconversion, DNA and RNA PCR; infection was con®rmed in four out of eight macaques pre-treated with P2K, two out of four pre-treated with D2S, one out of four pre-treated with N9, two out of four pre-treated with GD and four out of four pre-treated with D2S GD, a combination additive in vitro.
Interpretation: D2S and PRO-2000, novel inhibitors of HIV entry, showed evidence of protection in vivo, comparable to that seen with the virucide, N9. These data, together with the results of phase I and phase II studies in healthy women which have shown minimal toxicity, support plans for a phase III ef®cacy trial of chemically simple inhibitors of HIV entry with low toxicity, for the prevention of HIV infection in women.
Introduction
Over 80% of all HIV transmissions globally are through heterosexual intercourse, and in many circumstances women cannot successfully negotiate the use of condoms by their male partners. In these circumstances, alternative methods of protection for women against HIV transmission are urgently required. Vaginal agents capable of reducing HIV transmission either by disrupting virions or by preventing the entry of HIV into susceptible cells might protect women where condom use is infrequent or impossible.
To date, clinical studies of vaginal virucides have used licensed spermicidal agents such as nonoxynol-9 (N9). Three randomized clinical trials of different intravaginal products containing 75±100 mg N9 have failed to show signi®cant reduction in HIV transmission [1±5] . This is considered to be related, at least in part, to the toxicity of N9 on the vaginal mucosa, as repeated exposure may lead to in¯ammation and epithelial disruption, which may facilitate HIV infection [6, 7] . A phase I study of 100 mg N9, applied intravaginally daily for 7 days by 20 healthy volunteers, led to microscopic evidence of in¯ammation in seven (35%) women; the in¯ammatory in®ltrate comprised CD8 T cells and subepithelial macrophages [8] . Macrophages and Langerhans' cells are believed to be the ®rst target cells for HIV entry across the vaginal mucosa, and an increase in the number of these cells might promote transmission [9] . We therefore sought non-toxic, speci®c inhibitors of HIV infection that might be more suitable for long-term use intravaginally.
Synthetic and naturally occurring sulphated polymers, including dextrin-2-sulphate (D2S), PRO-2000, fucoidin and carrageenin exhibit potent inhibition of entry of diverse primary and laboratory-adapted HIV-1 isolates into primary and immortalized T cells and macrophages [10±15] . D2S is a sulphated sugar of approximately 33 kDa; P2K(P2K) is a naphthalene sulphonate polymer of approximately 5 kD [10, 11] . Molecules of this size are very poorly absorbed. Both have been investigated extensively in vitro, with reported 50% infectious concentrations (IC 50 ) of approximately 5 ìg/ml against laboratory adapted HIV-1 isolates (IIIB, RF), and 30±50 ìg/ml against primary HIV-1 isolates propagated in peripheral blood mononuclear cells (PBMC) [11, 13, 14] . D2S and P2K are strongly anionically charged and block fusion and entry of HIV into the target cell, probably through steric hindrance resulting from non-speci®c binding to charged regions on the viral envelope and the cell surface [15] .
The ionophore peptide antibiotic, gramicidin-D (GD), has also been reported to have antiretroviral activity, but unusually for a virucidal agent, with some speci®city for viral envelopes over cellular membranes [16] .
In phase I clinical studies in healthy women volunteers, D2S (56 subjects, 7 day exposure) and P2K (36 subjects, 14 day exposure) have shown no evidence of in¯ammation on post-exposure vaginal biopsy [17] ; phase II studies in sexually active women are ongoing.
D2S and P2K are relatively less active against simian immunode®ciency virus (SIV) in vitro; this appears to be unrelated to co-receptor usage, but is probably related to charge in the envelope V3 loop [15] . This study therefore established the activity of these agents in vitro against SHIV 89X6PD [18] , and undertook a challenge study with this virus intravaginally in rhesus macaques, using the novel vaginal microbicides, including the combination of GD and D2S.
Methods

In vitro experiments
Cell protection assay The activity of the candidate vaginal virucides in protecting cells from infection with SHIV 89X6PD was assessed in lymphoblastoid cells (C8166) at a concentration of 4 3 10 4 cells/well in 200 ìl RPM1-1640 medium (Sigma, Poole, Dorset, UK); cells were attached to sterile,¯at-bottomed 96-well tissue culture plates using poly-L-lysine (50 ìl of 50 ìg/ml). Following pre-coating with varying concentrations of candidate virucides, SHIV 89X6PD was added to each of the wells at concentrations of 10 or 100 tissue culture infectious doses (TCID)/well. The plates were then incubated at 378C in 5% CO 2 in air for 90 min; the medium was then removed, each well washed gently with phosphate buffered saline (PBS), 300 ìl fresh growth medium (RPMI-1640) added and the plates incubated for 70 h at 378C (5% CO 2 air). Following incubation, 200 ìl medium was removed from each well and the SIV p27 antigen titre was measured by ELISA (Coulter, Fullerton, California, USA). Dose± response curves were constructed and the IC 50 and 90% infectious concentration (IC 90 ) of the candidate virucides were recorded.
Selectivity index of candidate vaginal virucides
Details of this assay have been published previously [19, 20] . To assess the cytotoxicity of the candidate virucides (50% cytotoxic concentration, CC 50 ) uninfected C8166 cells were incubated for 72 h with serial dilutions of the compounds and then the cells were washed with PBS and suspended in 200 ìl RPM1-1640 growth medium containing 14 C protein hydrolysate (0.1 ìCi). Following a further incubation of 20 h, the incorporation of 14 C was measured on a beta counter (Packard, Pangbourne, UK 
Intravaginal administration of vaginal agents and virus
The vaginal agents and virus inoculations were applied intravaginally using a 1.0 ml tuberculin syringe. The monkeys were anaesthetized with an intramuscular injection of ketamine±HCl, 10 mg/kg body weight, and then positioned in their cages resting on the sternum and knees so the posterior was slightly higher than the head. The vaginal agents were administered by applying a small amount at the opening of the vagina for lubrication, then inserting the syringe to the cervix and dispensing the agents into the vagina as the syringe was withdrawn. Fifteen min later the virus was administered in a similar manner (without additional lubrication). An additional dose(s) of ketamine was used so that the animals remained anesthetized and in position for approximately 30±45 min post-dosing. The procedure was repeated after 3 h.
Determination of SHIV infection
Virus isolation by co-culture PBMC were separated over a ®coll gradient and approximately 1 3 10 7 cells were co-cultured in a 2 : 1 ratio with CEMx174 cells; additional CEMx174 cells were added over time if required. Supernatant samples were collected after 21 days of culture, and stored frozen at À708C until analysis with the Coulter p27 antigen assay kit.
SIV plasma RNA Plasma was separated from whole blood by centrifugation and stored frozen at À778C. Week 2 and 12 samples were sent to Chiron Reference Laboratory, (Emeryville, California, USA) for SIV RNA analysis using the Chiron bDNA assay (Bayer, Newberry, UKlimit of detection 1500 copies/ml).
Virus isolation and DNA detection from tissues Samples of lymph nodes (axillary, inguinal, and iliac) and spleen were collected at post-mortem during week 13 from animals that were virus isolation-negative during week 9 and isolated cells were co-cultured with CEMx174 cells (see above). DNA was extracted from this tissue and qualitative SIV DNA detection was performed by PCR.
SIV antibody detection
Antibodies to SIV gag p27 (EVA 643 antigen) and gp120 (W61D EVA 648 antigen) were assayed by ELISA, from plasma at week 13 only, by serial dilution and log 10 end-point titration.
Results
D2S and P2K are active against SHIV 89X6PD , with IC 50 of 42 and 54 ìg/ml (see Table 1 ). Both have a high selectivity index for SHIV 89X6PD (Table 1) , and both retain antiviral activity in the presence of seminal plasma (data not shown). GD has an IC 50 against SHIV 89X6PD of approximately 0.2 ìg/ml, with a CC 50 of 4 ìg/ml, a selectivity index of 20. There is a doserelated additive effect of D2S and GD: adding 100 ng/ ml GD reduces the IC 50 of D2S from approximately 5 ìg/ml for D2S alone, to 500 ng/ml for the combination. N9 has an IC 50 of 25 ìg/ml, with no evidence of selectivity in the cytotoxicity assay.
The macaques were challenged with two doses of 1 3 10 4 TCID SHIV 89X6PD , in 0.87 ml, given 3 h apart. Six groups of four monkeys were pre-treated 15 min before each virus innoculation with 1 ml of: N9 at 37.5 mg/ml; D2S at 10 mg/ml; P2K at 20 mg/ml and 40 mg/ml; GD at 200 ng/ml; and a combination of GD 200ng/ml with D2S 10 mg/ml. Four control monkeys were not pre-treated. Infection was determined by bDNA detection of SIV RNA in plasma, and by SIV isolation from macaque PBMC. Animals negative by these assays were sacri®ced at week 13 and examined for antibody to SIV Gag and Env by ELISA. 
Nonoxynol-9
(positive control) 37.5 37.5 37.5 37.5
Dextrin-2-sulfate 10 10 10 10 5A 5B 5C 5D 
Dextrin Post-mortem tissue from axillary, inguinal and iliac lymph nodes and spleen were examined by viral coculture and by SIV DNA PCR.
The challenge results are shown in Table 2 ; only three out of four control macaques were infected. In the N9 arm one out of four macaque was infected compared with tow out of four in the D2S and four out of eight in the P2K arms, with some indication of a doserelated effect of P2K. At the lower dose P2K (20 mg/ ml), three out of four macaques were infected, whereas in the higher dose arm (40 mg/ml P2K) only one out of four macaques was infected. Whereas two out of four monkeys were infected in the GD alone arm, all of the monkeys in the GD/D2S combination arm were infected, even though this combination of a virucidal agent with an entry inhibitor was additive in vitro.
Discussion
This study has shown that it is possible to protect 50± 75% of macaques against a highly pathogenic SHIV 89X6PD challenge through the vaginal route, by the use of non-virucidal HIV entry inhibitors such as D2S or PRO-2000. The level of protection is similar to that seen with the virucidal agent, N9. Although the numbers are too small for signi®cance, the addition of the low-dose virucidal gramicidin to D2S does not appear to have led to enhanced protection against challenge.
The failure to infect all four control macaques despite two vaginal challenges 3 h apart with . 1 3 10 4 TCID of virus stock (10 7 SHIV RNA copies/ml) indicates that vaginal infection in macaques, a non-physiological route of transmission, is dif®cult to achieve consistently. Nonetheless, these results suggest that inhibitors of HIV entry may protect against SHIV vaginal challenge in macaques. Moreover, our previous phase I studies in women show that both D2S and P2K are well tolerated in regular use, and do not induce the in¯ammation observed with N9 [7] .
The macaque challenge data do not support the combination of the virucidal agent, GD, with D2S, despite additivity in vitro. Although this result is currently unexplained, the concept of combining low doses of virucidal and high doses of HIV entry inhibitors remains attractive, and merits further exploration.
The decision of whether to progress these agents to phase III study on the basis of in vitro activity, low toxicity in volunteers and animal challenge data is not straightforward. As 100% infection of control animals was not achieved, it is unclear that further macaque challenge studies will help the selection of candidate agents. Assuming that phase II studies in target populations are well tolerated, we believe that these data support the development of phase III randomized clinical trials of the ef®cacy of D2S and P2K in large populations at risk of HIV infection. Although protection was incomplete in the macaque model, the natural challenge situation is dif®cult to simulate experimentally. Vaginal agents with a 50% ef®cacy could have a signi®cant effect on population rates of HIV acquisition. In the context of irregular condom use, vaginal microbicides could halve the risk of HIV transmission per act of intercourse. A combination of intermittent use of condoms, which effectively reduce the number of exposures, with vaginal agents that reduce the risk per exposure, is likely to exert an additive effect on the reduction of HIV transmission.
